TrialEuropean urology oncology2021

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

Michael J Morris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.